RGRepligen RGEN · NASDAQ
$178.94 +3.14% (+$5.45)
- Market cap
- $11.4B
- Enterprise value
- $11.4B
- P/E
- -
- Forward P/E
- 97.5x
- PEG
- -
- P/S
- 14.2x
- P/FCF
- 107.7x
- EV/EBITDA
- 94.1x
- ROIC
- -1.0%
- Gross margin
- 51.1%
- Net margin
- -1.5%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.3x
- Beta
- 1.12
- Free float
- 95.4%
About the company
Repligen is an American company engaged in the development and production of materials used in the production of biological drugs. Based in Waltham, Massachusetts, the company was incorporated in Delaware in 1981. Repligen is a public company listed on the NASDAQ stock exchange under the symbol RGEN.
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Olivier Loeillot
Employees
2,000
Headquarters
Waltham
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Analysts expect revenue to grow by 15% this fiscal year.
- What to watch: Earnings per share fell by 36% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 13 USD is left as free cash.
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $727.0M against $692.2M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number